Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours
Cheryl A. London,Tamra Mathie,Nicole Stingle,Craig A. Clifford,Siobhan Haney,Mary K. Klein,Linda Beaver,Kate Vickery,David M. Vail,Betsey Hershey,Susan Ettinger,Andrew Vaughan,Francisco J. Alvarez,Lorin Hillman,Mike Kiselow,Doug H. Thamm,Mary Lynn Higginbotham,Meredith Gauthier,Erika L. Krick,Brenda Phillips,Tracy Ladue,Pam Jones,Jeffery Bryan,Virginia L. Gill,Andrew Novasad,Lisa Fulton,Janet K. Carreras,C. J. McNeill,Carolyn J. Henry,Sarah Gillings +29 more
Reads0
Chats0
TLDR
Preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours is provided, although future prospective studies are necessary to define its true activity.Abstract:
The purpose of this study was to provide an initial assessment of the potential biologic activity of toceranib phosphate (Palladia®, Pfizer Animal Health, Madison, NJ, USA) in select solid tumours in dogs. Cases in which toceranib was used to treat dogs with apocrine gland anal sac adenocarcinoma (AGASACA), metastatic osteosarcoma (OSA), thyroid carcinoma, head and neck carcinoma and nasal carcinoma were included. Clinical benefit (CB) was observed in 63/85 (74%) dogs including 28/32 AGASACA [8 partial response (PR), 20 stable disease (SD)], 11/23 OSAs (1 PR and 10 SD), 12/15 thyroid carcinomas (4 PR and 8 SD), 7/8 head and neck carcinomas [1 complete response (CR), 5 PR and 1 SD] and 5/7 (1 CR and 4 SD) nasal carcinomas. For dogs experiencing CB, the median dose of toceranib was 2.8 mg kg(-1) , 36/63 (58.7%) were dosed on a Monday/Wednesday/Friday basis and 47/63 (74.6%) were treated 4 months or longer. Although these data provide preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours, future prospective studies are necessary to define its true activity.read more
Citations
More filters
Journal ArticleDOI
Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.
TL;DR: Clinical and molecular evidence suggests that human and canine OSA share many key features, including tumor location, presence of microscopic metastatic disease at diagnosis, development of chemotherapy-resistant metastases, and altered expression/activation of several proteins, supporting the notion that these diseases are similar at the molecular level.
Journal ArticleDOI
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
TL;DR: It is revisited how the heterogenous nature of osteosarcoma as well as acquired and intrinsic resistance to chemotherapy can account for stagnation in therapy improvement.
Journal ArticleDOI
Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma
TL;DR: Although choice of protocol did not result in significant differences in DFI or ST, the CARBO6 protocol resulted in a lower proportion of dogs experiencing AEs, which could be advantageous in maintaining high quality of life during treatment.
References
More filters
Journal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Journal ArticleDOI
Sunitinib: From Rational Design to Clinical Efficacy
Laura Q M Chow,S. Gail Eckhardt +1 more
TL;DR: The clinical benchmarking of this small-molecule inhibitor of members of the split-kinase domain family of RTKs will lead to additional insights regarding the biology, potential biomarkers, and clinical utility of agents that target multiple signaling pathways in tumor, stromal, and endothelial compartments.
Journal ArticleDOI
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Vandana Gupta-Abramson,Andrea B. Troxel,Anoma Nellore,Kanchan Puttaswamy,Maryann Redlinger,Kathy Ransone,Susan J. Mandel,Keith T. Flaherty,Laurie A. Loevner,Peter J. O'Dwyer,Marcia S. Brose +10 more
TL;DR: Sorafenib has clinically relevant antitumor activity in patients with metastatic, iodine-refractory thyroid carcinoma, with an overall clinical benefit rate of 77%, median PFS of 79 weeks, and an overall acceptable safety profile.
Journal ArticleDOI
Metronomic chemotherapy: new rationale for new directions.
TL;DR: The latest clinical trials of metronomic chemotherapy in adult and pediatric cancer patients and potential new mechanisms of action, such as restoration of anticancer immune response and induction of tumor dormancy are discussed.
Journal ArticleDOI
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos,Matthew D. Ringel,Michael V. Knopp,Nathan Hall,Mark A. King,Robert Stevens,Jiachao Liang,Paul E. Wakely,Vasyl Vasko,Motoyasu Saji,Jennifer Rittenberry,Lai Wei,Daria Arbogast,Minden Collamore,John J. Wright,Michael R. Grever,Manisha H. Shah +16 more
TL;DR: Sorafenib is reasonably well-tolerated therapy with clinical and biologic antitumor activity in metastatic PTC and four of 10 paired tumor biopsies from PTC patients showed a reduction in levels of vascular endothelial growth factor receptor phosphorylated, ERK phosphorylation, and in VEGF expression during sorafenIB therapy.